FLT3 inhibitors have transformed the therapeutic landscape for FLT3-mutated AML [75] with single agent gilteritinib more effective than chemotherapy for relapsed disease [56, 58, 59, 76, 77]. This evidence concerns the gene FLT3 and acute myeloid leukemia.